This site is intended for healthcare professionals only
LoginRegister
Zydus Told to Withdraw Unmarketed Strengths, Conduct Phase IV Trial for Approved Combinations OnlyZydus Healthcare gets CDSCO Panel nod to conduct Phase III CT of Glycopyrrolate plus Indacaterol...
Himachal to develop medical device park independentlyMedical device manufacturers need to resubmit MSC and NCC as CDSCO launches Automated Process
AstraZeneca Imfinzi recommended for approval in EU for adults with muscle-invasive bladder cancerAstraZeneca Gets CDSCO Panel Nod To study Tezepelumab
US tariffs on pharma sector would be counterproductive for Americans, says Wockhardt ChairmanUS tariffs on pharma sector would be counterproductive for Americans, says Wockhardt Chairman
Novartis arm commences tender offer to acquire Regulus TherapeuticsNovartis plans to invest USD 23 billion over next 5 years in US based infrastructure
Pomalyst monopoly case: Bristol Myers wins dismissal of lawsuitPomalyst monopoly case: Bristol Myers wins dismissal of lawsuit
Pharmacy Practice RegulationsD.Pharm To Remain Minimum Qualification To Become Pharmacist in Bihar: Patna HC
Morepen Labs plans to employ over 1000 professionalsMorepen Labs plans to employ over 1000 professionals
Raid at quack clinic in Telangana, drugs including Amoxycillin seizedRaid at quack clinic in Telangana, drugs including Amoxycillin seized
USFDA grants Fast Track Designation to Zydus Usnoflast for amyotrophic lateral sclerosisZydus Lifesciences bags USFDA nod for Duchenne muscular dystrophy drug Jaythari
JnJ Nipocalimab gets USFDA Fast Track designation for Sjogrens diseaseJohnson & Johnson gets CDSCO Panel for additional indication of Amivantamab Liquid Concentrate for...
Intas Gets CDSCO Panel Nod for PertuzumabSubmit Phase III CT data with Pk and Pd data: CDSCO Panel Tells Intas Pharmaceuticals on Human von...
X